Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Neurofibromatosis 1 1Neoplasm Metastasis 1Leukemia, Myelomonocytic, Juvenile 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Follicular 1

Interventions

AZD 6244 3mirdametinib 2Sirolimus 2Everolimus 2trametinib 1tipifarnib 1pirfenidone 1peginterferon alfa-2b 1omipalisib 1cediranib 1binimetinib 1Vincristine 1Vinblastine 1Temozolomide 1Surveys and Questionnaires 1Sunitinib 1Radiotherapy 1Methotrexate 1Magnetic Resonance Imaging 1Lovastatin 1Lenalidomide 1Inhalation 1Ifosfamide 1Gadolinium DTPA 1Fluorodeoxyglucose F18 1Filgrastim 1Etoposide 1Doxorubicin 1Dosage Forms 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurofibromatosis 1 × omipalisib × Clear all
NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
10 enrolled 11 charts
CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡